Female sexual medicine raw materials

Raloxifene
Indication:Raloxifene is indicated for the treatment and prevention of osteoporosis in postmenopausal women, for reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis. For either osteoporosis treatment or prevention, supplemental calcium and/or vitamin D should be add…
Tamoxifen
Product Description: Tamoxifen is an antagonist of the estrogen receptor in breast tissue. It has been the standard endocrine (anti-estrogen) therapy for hormone-positive early breast cancer in post-menopausal women, although aromatase inhibitors have been proposed.
Cyclofenil
Product Description:Cyclofenil is a selective estrogen receptor modulator. It was investigated as a possible treatment for scleroderma in the 1980s, but was found to be ineffective. Later study of its efficacy in treating Raynaud's phenomenon in people with scleroderma also found no statistically si…
Clomifene
Product Description:Clomifene (INN) or clomiphene (USAN and former BAN) or Clomid or Clomifert is a selective estrogen receptor modulator (SERM), which increases production of gonadotropins by inhibiting negative feedback on the hypothalamus. It is used mainly for ovarian stimulation in female infer…
Ethylestrenol
Product Description:Ethylestrenol (Maxibolin, Orabolin) is an anabolic steroid with some progesterone-like activity, and little androgenic activity. It is a nandrolone derivative and lacks the 3-keto functional group.
Natural Female Reyouth Formula
Dosage: 100-200mg/time,the effect is proportional to dose. Character: Oily liquid ,Its salt is light yellow powder, odorless, slightly bitter, soluble in alcohol, not completely dissolve in water.
Natural Female Sexual Desire Formula
Usage:80-150mg/time, the effect is proportional to dose. Character:white powder, odorless, slightly bitter, and completely soluble in water and alcohol. Indications:suitable for frigidity crowd of women, it’s mainly used to enhance female sexual desrie , shorten the telogen phase of the cycle, exten…